Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders

Abroad (travel likely)Recruiting

Conditions

Primary Immunodeficiency Diseases (PID)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Hospitals Leuven,, Leuven, Vlaams-Brabant, Belgium
Contact: Study coordinator (Cecilia Iglesias Herrero, MPharm) · cecilia.iglesiasherrero@kuleuven.be

Study leads

Rik Schrijvers, MD, PhD
Principal Investigator
UZ Leuven

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Primary Immunodeficiency Diseases (PID)

Abroad (travel likely)Recruiting

Tokyo, Japan

Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)

Primary Immunodeficiency Diseases

Abroad (travel likely)RecruitingPHASE3

Cherkasy, Ukraine · Chernivtsi, Ukraine

Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies

Immunologic Deficiency Syndromes · Primary Immune Deficiency (PID)

Abroad (travel likely)Recruiting

Zurich, Switzerland